Table 2.

Cox proportional hazards multivariable analysis for overall and progression-free survival outcomes

	Overall Survival			Progression-Free Survival
	aHR	95% CI	P	aHR	95% CI	P
Cisplatin
> / = 5 Cycles	Reference			Reference
< 5 Cycles	2.94	1.58–5.47	< 0.001	2.32	1.29–4.17	0.005
Gender
Male	Reference			Reference
Female	0.76	0.31–1.87	0.55	0.42	0.15–1.18	0.1
Smoker
Never	Reference			Reference
Former	1.74	0.76–3.98	0.19	1.89	0.81–4.39	0.14
Current	1.61	0.58–4.49	0.36	1.38	0.51–3.75	0.53
Age
< 65	Reference			Reference
65 or older	0.85	0.46–1.58	0.62	0.73	0.40–1.33	0.3
KPS
90–100	Reference			Reference
< 90	1.93	1.02–3.66	0.04	1.91	1.04–3.50	0.04
Race
White	Reference			Reference
Other	0.94	0.38–2.33	0.89	1.14	0.48–2.70	0.76
BMI
Normal	Reference			Reference
Underweight	0.53	0.12–2.29	0.39	2.9	0.51–16.59	0.23
Overweight	0.52	0.26–1.05	0.07	0.78	0.39–1.56	0.48
Obese	0.88	0.38–2.08	0.78	1.13	0.51–2.49	0.77
Not available	< 0.001	< 0.001-Inf	1	< 0.001	< 0.001-Inf	1
Site
Oropharynx	Reference			Reference
Larynx	0.46	0.19–1.12	0.09	0.6	0.26–1.40	0.24
Oral cavity	1.91	0.17–21.13	0.6	Jan-84	0.17–20.13	0.62
Other	1.1	0.49–2.45	0.82	1.06	0.48–2.36	0.89
T staging
1–2	Reference			Reference
3–4	2.54	1.30–4.96	0.006	2.71	1.40–5.23	0.003
N staging
0–1	Reference			Reference
2–3	1.37	0.58–3.20	0.47	1.46	0.65–3.32	0.36
HPV
Negative	Reference			Reference
Positive	0.54	0.20–1.46	0.23	0.76	0.29–1.97	0.57
Not available	0.92	0.38–2.23	0.86	1.31	0.57–3.03	0.52

aHR Adjusted hazards ratio, 95% CI 95% Confidence interval, BMI Body mass index, KPS Karnofsky performance status, HPV Human papillomavirus